Lululemon Athletica Inc. (LULU) PT Lowered to $191 at JPMorgan
Get Alerts LULU Hot Sheet
Rating Summary:
13 Buy, 36 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 3 | Down: 6 | New: 22
Join SI Premium – FREE
JPMorgan analyst Matthew Boss lowered the price target on Lululemon Athletica Inc. (NASDAQ: LULU) to $191.00 (from $224.00) while maintaining a Neutral rating.
The analyst comments "LULU reported 2Q EPS of $3.10 (above Street $2.87) driven by +7% Y/Y revenue growth (= Street), gross margin contraction of -110bps Y/Y to 58.5% (above Street 57.5% / mgmt’s 57.6% guide), and SG&A deleverage of -90bps to 37.7% (vs. Street 38.6%), translating to an operating margin of 20.7% (above Street 18.9%). Digging deeper, 2Q same-store-sales grew +1% c/c (below the Street at +2.4%) primarily driven by negative 3% Americas comps c/c (below Street -0.8%), which sequentially worsened over the course of the quarter despite taking higher than planned markdowns (-60bps headwind vs. mgmt’s -20-40bps forecast). Looking ahead, management lowered FY25 EPS to $12.77-$12.97 (-12% below midpoint of prior $14.58-$14.78 guide) based on (i) lowered +2-4% reported revenue growth y/y (vs. prior +5-7% guide and Street +5.5%), or +4-6% excluding the lap of the 53rd week, and (ii) lowered FY25 operating margins to down -390bps to 19.8% (below 22.1% prior & Street 21.6%). Near-term, management guided 3Q25 EPS to $2.18-$2.23 (~24% below the Street at $2.89) based on +3-4% reported revenue growth Y/Y (vs. Street +6.7%) and operating margins down - 560bps Y/Y to 14.9% (vs. Street 18.8%). This implies 4Q EPS of $4.89-$5.04 (~17% below Street $5.98) based on -2.5% reported revenue growth Y/Y (vs. Street 2.5%) and operating margins down -550bps Y/Y to ~23.4% (vs. Street 27.1%)."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Downgrades Principal Financial Group (PFG) to Underperform
- JPMorgan Downgrades Wipro Ltd. (WPRO:IN) (WIT) to Underweight
- Barclays Starts SAB Biotherapeutics (SABS) at Overweight
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
JPMorgan, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share